Majid Zeidi

Majid Zeidi

Auto-generated profile, based on publicly available information

Majid Zeidi

Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, U.S. Department of Veterans Affairs, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
HKHee Joo Kim
Hee Joo Kim
MZM. Zeidi
M. Zeidi
DBD. Bonciani
D. Bonciani
SPS.M. Pena
S.M. Pena
JTJ. Tiao
J. Tiao
VWVictoria P WERTH
Victoria P WERTH

28 April 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
VWVictoria P WERTH
Victoria P WERTH
EHEmily Hejazi
Emily Hejazi
SPSandra M. Pena
Sandra M. Pena
JHJessica Haber
Jessica Haber
MZMajid Zeidi
Majid Zeidi
BWBarbara White
Barbara White

1 February 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MZMajid Zeidi
Majid Zeidi
HKHee Joo Kim
Hee Joo Kim
VWVictoria P WERTH
Victoria P WERTH

1 November 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ERElizabeth S. Robinson
Elizabeth S. Robinson
PAPaul Alves
Paul Alves
MBMuhammad M. Bashir
Muhammad M. Bashir
MZMajid Zeidi
Majid Zeidi
RFRui Feng
Rui Feng
VWVictoria P WERTH
Victoria P WERTH

1 April 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CBChristina E. Bax
Christina E. Bax
SCSrita Chakka
Srita Chakka
JCJosef Symon S. Concha
Josef Symon S. Concha
MZMajid Zeidi
Majid Zeidi
VWVictoria P WERTH
Victoria P WERTH

1 October 2017 in Journal of Investigative Dermatology Symposium Proceedings
Verified
Journal Article
Open access
PDF file
PAPaul Alves
Paul Alves
MBMuhammad M. Bashir
Muhammad M. Bashir
MWMaria Wysocka
Maria Wysocka
MZMajid Zeidi
Majid Zeidi
RFRui Feng
Rui Feng
VWVictoria P WERTH
Victoria P WERTH
Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE). Although hydroxychloroquine (HCQ) is frequently used, addition of quinacrine (QC) has shown additional clinical effects when combined with HCQ. To quantify the effects of HCQ versus QC in suppressing secretion of tumor necrosis factor-α (TNF-α) and IFN-α from the peripheral blood mononuclear cells of DM and CLE patients, lipopolysaccharide-stimulated and control peripheral blood mononuclear cells from DM and CLE patients and control subjects were analyzed for the effect of HCQ and QC on TNF-α and IFN-α production using ELISA testing. Flow cytometry showed the effects of these therapies on intracellular TNF-α in myeloid dendritic cells and monocytes of DM patients and control subjects. QC significantly suppressed TNF-α relative to HCQ from unstimulated and lipopolysaccharide-stimulated peripheral blood mononuclear cells of DM and CLE patients (P < 0.0001). It suppressed IFN-α as significantly as HCQ from cytosine phosphodiester guanine–stimulated peripheral blood mononuclear cells of DM and CLE patients (P < 0.0001). Flow cytometry showed that QC significantly suppressed intracellular expression of TNF-α from the lipopolysaccharide-stimulated myeloid dendritic cells and monocytes of DM patients (P-values ≤ 0.0008). In conclusion, QC likely has a different mechanism of action than HCQ, given the broader inhibition of proinflammatory cytokines, including both TNF-α and IFN-α.